Nonviral vector-mediated RNA interference: Its gene silencing characteristics and important factors to achieve RNAi-based gene therapy

Advanced Drug Delivery Reviews

Volumn 61, Issue 9, 2009, Pages 760-766

  Takahashi, Yuki ^a   Nishikawa, Makiya ^a   Takakura, Yoshinobu ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Duration; Hydrodynamic delivery; In vivo delivery; Short hairpin RNA; Side effect

Indexed keywords

DURATION; GENE SILENCING; GENE THERAPY; HAIRPIN RNA; IN VIVO DELIVERY; IN-VIVO; NONVIRAL VECTORS; PLASMID DNA; RECENT PROGRESS; RNA INTERFERENCE; SHORT HAIRPIN RNA; SIDE EFFECT; SMALL INTERFERING RNA (SIRNA); TARGET CELLS;

FLUID DYNAMICS; GENETIC ENGINEERING; HYDRODYNAMICS; INTERNET; RNA; TARGETS;

NUCLEIC ACIDS;

MESSENGER RNA; PLASMID DNA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

DNA VECTOR; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; EXPRESSION VECTOR; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; RNA INTERFERENCE; RNA TRANSCRIPTION;

ANIMALS; GENE SILENCING; GENE THERAPY; HUMANS; PROMOTER REGIONS, GENETIC; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 65749119809     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.04.006     Document Type: Review

References (84)

1. Tuschl T., Zamore P.D., Lehmann R., Bartel D.P., and Sharp P.A. Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev. 13 (1999) 3191-3197
2. Caplen N.J., Parrish S., Imani F., Fire A., and Morgan R.A. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 9742-9747
3. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001) 494-498
4. De Souza A.T., Dai X., Spencer A.G., Reppen T., Menzie A., Roesch P.L., He Y., Caguyong M.J., Bloomer S., Herweijer H., Wolff J.A., Hagstrom J.E., Lewis D.L., Linsley P.S., and Ulrich R.G. Transcriptional and phenotypic comparisons of Ppara knockout and siRNA knockdown mice. Nucleic Acids Res. 34 (2006) 4486-4494
5. Miyagishi M., Hayashi M., and Taira K. Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug Dev. 13 (2003) 1-7
6. Sui G., Soohoo C., Affar E.B., Gay F., Shi Y., and Forrester W.C. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 5515-5520
7. Brummelkamp T.R., Bernards R., and Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 296 (2002) 550-553
8. Yu J.Y., Deruiter S.L., and Turner D.L. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 6047-6052
9. Tuschl T. Expanding small RNA interference. Nat. Biotechnol. 20 (2002) 446-448
10. Kobayashi N., Matsui Y., Kawase A., Hirata K., Miyagishi M., Taira K., Nishikawa M., and Takakura Y. Vector-based in vivo RNA interference: dose- and time-dependent suppression of transgene expression. J. Pharmacol. Exp. Ther. 308 (2004) 688-693
11. Hayafune M., Miyano-Kurosaki N., Park W.S., Moori Y., and Takaku H. Silencing of HIV-1 gene expression by two types of siRNA expression systems. Antivir. Chem. Chemother. 17 (2006) 241-249
12. Lakka S.S., Gondi C.S., Dinh D.H., Olivero W.C., Gujrati M., Rao V.H., Sioka C., and Rao J.S. Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas. J Biol Chem. 280 (2005) 21882-21892
13. Zhu X., Santat L.A., Chang M.S., Liu J., Zavzavadjian J.R., Wall E.A., Kivork C., Simon M.I., and Fraser I.D.C. A versatile approach to multiple gene RNA interference using microRNA-based short hairpin RNAs. BMC Mol. Biol. 8 (2007)
14. Papadakis E.D., Nicklin S.A., Baker A.H., and White S.J. Promoters and control elements: Designing expression cassettes for gene therapy. Curr. Gene Ther. 4 (2004) 89-113
15. Takahashi Y., Yamaoka K., Nishikawa M., and Takakura Y. Quantitative and temporal analysis of gene silencing in tumor cells induced by small interfering RNA or short hairpin RNA expressed from plasmid vectors. J. Pharm. Sci. 98 (2009) 74-80
16. Boden D., Pusch O., Lee F., Tucker L., Shank P.R., and Ramratnam B. Promoter choice affects the potency of HIV-1 specific RNA interference. Nucleic Acids Res. 31 (2003) 5033-5038
17. Choy E.Y.W., Kok K.H., Tsao S.W., and Jin D.Y. Utility of Epstein-Barr virus-encoded small RNA promoters for driving the expression of fusion transcripts harboring short hairpin RNAs. Gene Ther. 15 (2008) 191-202
18. Czauderna F., Santel A., Hinz M., Fechtner M., Durieux B., Fisch G., Leenders F., Arnold W., Giese K., Klippel A., and Kaufmann J. Inducible shRNA expression for application in a prostate cancer mouse model. Nucleic Acids Res. 31 (2003)
19. Hosono T., Mizuguchi H., Katayama K., Xu Z.L., Sakurai F., Ishii-Watabe A., Kawabata K., Yamaguchi T., Nakagawa S., Mayumi T., and Hayakawa T. Adenovirus vector-mediated doxycycline-inducible RNA interference. Hum. Gene Ther. 15 (2004) 813-819
20. Matthess Y., Kappel S., Späkuch B., Zimmer B., Kaufmann M., and Strebhardt K. Conditional inhibition of cancer cell proliferation by tetracycline- responsive, H1 promoter-driven silencing of PLK1. Oncogenes 24 (2005) 2973-2980
21. Ill C.R., and Chiou H.C. Gene therapy progress and prospects: recent progress in transgene and RNAi expression cassettes. Gene Ther. 12 (2005) 795-802
22. Zhou H., Xia X.G., and Xu Z. An RNA polymerase II construct synthesizes short-hairpin RNA with a quantitative indicator and mediates highly efficient RNAi. Nucleic Acids Res. 33 (2005)
23. Xing Y., Liu M., Du Y., Qu F., Li Y., Zhang Q., Xiao Y., Zhao J., Zeng F., and Xiao C. Tumor cell-specific blockade of CXCR4/SDF-1 interactions in prostate cancer cells by hTERT promoter induced CXCR4 knockdown: a possible metastasis preventing and minimizing approach. Cancer Biol. Ther. 7 (2008) 1840-1849
24. Chen S.W., Chen Y.X., Zhang X.R., Qian H., Chen W.Z., and Xie W.F. Targeted inhibition of platelet-derived growth factor receptor-beta subunit in hepatic stellate cells ameliorates hepatic fibrosis in rats. Gene Ther. 15 (2008) 1424-1435
25. Giering J.C., Grimm D., Storm T.A., and Kay M.A. Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol Ther. 16 (2008) 1630-1636
26. Zhao W., Xu Y., Kong D., Liu R., Zhang Z., Jin C., and Xiu Y. Tissue-selective RNA interference in prostate cancer cell using prostate specific membrane antigen promoter/enhancer(). Urol. Oncol. (2008)
27. Grimm D., Streetz K.L., Jopling C.L., Storm T.A., Pandey K., Davis C.R., Marion P., Salazar F., and Kay M.A. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441 (2006) 537-541
28. Jenke A.C.W., Wilhelm A.D., Orth V., Lipps H.J., Protzer U., and Wirth S. Long-term suppression of hepatitis B virus replication by short hairpin RNA expression using the scaffold/matrix attachment region-based replicating vector system pEPI-1. Antimicrob. Agents Chemother. 52 (2008) 2355-2359
29. Rumpold H., Salvador C., Wolf A.M., Tilg H., Gastl G., and Wolf D. Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors. Biochem. Biophys Res Commun. 361 (2007) 549-554
30. Chen Z.J., Kren B.T., Wong P.Y.P., Low W.C., and Steer C.J. Sleeping Beauty-mediated down-regulation of huntingtin expression by RNA interference. Biochem. Biophys. Res. Commun. 329 (2005) 646-652
31. Kawano H., Nishikawa M., Mitsui M., Takahashi Y., Kako K., Yamaoka K., Watanabe Y., and Takakura Y. Improved anti-cancer effect of interferon gene transfer by sustained expression using CpG-reduced plasmid DNA. Int. J. Cancer 121 (2007) 401-406
32. Escoffre J.M., Debin A., Reynes J.P., Drocourt D., Tiraby G., Hellaudais L., Teissie J., and Golzio M. Long-lasting in vivo gene silencing by electrotransfer of shRNA expressing plasmid. Technol Cancer Res. Treat. 7 (2008) 109-116
33. Morrissey D.V., Blanchard K., Shaw L., Jensen K., Lockridge J.A., Dickinson B., Mcswiggen J.A., Vargeese C., Bowman K., Shatter C.S., Polisky B.A., and Zinnen S. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 41 (2005) 1349-1356
34. Haupenthal J., Baehr C., Kiermayer S., Zeuzem S., and Piiper A. Inhibition of RNAse A family enzymes prevents degradation and loss of silencing activity of siRNAs in serum. Biochem. Pharmacol. 71 (2006) 702-710
35. Elmén J., Thonberg H., Ljungberg K., Frieden M., Westergaard M., Xu Y., Wahren B., Liang Z., Ørum H., Koch T., and Wahlestedt C. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res. 33 (2005) 439-447
36. Kawabata K., Takakura Y., and Hashida M. The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake. Pharm. Res. 12 (1995) 825-830
37. Adami R.C., Collard W.T., Gupta S.A., Kwok K.Y., Bonadio J., and Rice K.G. Stability of peptide-condensed plasmid DNA formulations. J. Pharm. Sci. 87 (1998) 678-683
38. Peek A.S., and Behlke M.A. Design of active small interfering RNAs. Curr. Opin. Mol. Ther. 9 (2007) 110-118
39. Krueger U., Bergauer T., Kaufmann B., Wolter I., Pilk S., Heider-Fabian M., Kirch S., Artz-Oppitz C., Isselhorst M., and Konrad J. Insights into effective RNAi gained from large-scale siRNA validation screening. Oligonucleotides 17 (2007) 237-250
40. Corey D.R. Chemical modification: the key to clinical application of RNA interference?. J. Clin. Invest. 117 (2007) 3615-3622
41. Takahashi Y., Yamaoka K., Nishikawa M., and Takakura Y. Moment analysis for kinetics of gene silencing by RNA interference. Biotechnol. Bioeng. 93 (2006) 816-819
42. Mcanuff M.A., Rettig G.R., and Rice K.G. Potency of siRNA versus shRNA mediated knockdown in vivo. J. Pharm. Sci. 96 (2007) 2922-2930
43. Zeng Y., and Cullen B.R. RNA interference in human cells is restricted to the cytoplasm. RNA 8 (2002) 855-860
44. Wagstaff K.M., and Jans D.A. Nucleocytoplasmic transport of DNA: enhancing non-viral gene transfer. Biochem. J. 406 (2007) 185-202
45. Shen L., Evel-Kabler K., Strube R., and Chen S.Y. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat. Biotechnol. 22 (2004) 1546-1553
46. Mantei A., Rutz S., Janke M., Kirchhoff D., Jung U., Patzel V., Vogel U., Rudel T., Andreou I., Weber M., and Scheffold A. siRNA stabilization prolongs gene knockdown in primary T lymphocytes. Eur. J. Immunol. 38 (2008) 2616-2625
47. Matsui Y., Kobayashi N., Nishikawa M., and Takakura Y. Sequence-specific suppression of mdr1a/1b expression in mice via RNA interference. Pharm. Res. 22 (2005) 2091-2098
48. Wesche-Soldato D.E., Chung C.S., Lomas-Neira J., Doughty L.A., Gregory S.H., and Ayala A. In vivo delivery of caspase-8 or Fas siRNA improves the survival of septic mice. Blood 106 (2005) 2295-2301
49. Zender L., Hütker S., Liedtke C., Tillmann H.L., Zender S., Mundt B., Waltemathe M., Gösling T., Flemming P., Malek N.P., Trautwein C., Manns M.P., Kühnel F., and Kubicka S. Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 7797-7802
50. Zhang G., Budker V., and Wolff J.A. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum. Gene Ther. 10 (1999) 1735-1737
51. Liu F., Song Y.K., and Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6 (1999) 1258-1266
52. Takahashi Y., Nishikawa M., and Takakura Y. Suppression of tumor growth by intratumoral injection of short hairpin RNA-expressing plasmid DNA targeting β-catenin or hypoxia-inducible factor 1α. J. Control Release 116 (2006) 90-95
53. Zhang Y., Zhang Y.F., Bryant J., Charles A., Boado R.J., and Pardridge W.M. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin. Cancer Res. 10 (2004) 3667-3677
54. Zhao J., Wei X.L., Jia Y.S., and Zheng J.Q. Silencing of herg gene by shRNA inhibits SH-SY5Y cell growth in vitro and in vivo. Eur. J. Pharmacol. 579 (2008) 50-57
55. Takahashi Y., Nishikawa M., and Takakura Y. Inhibition of tumor cell growth in the liver by RNA interference-mediated suppression of HIF-1alpha expression in tumor cells and hepatocytes. Gene Ther. 15 (2008) 572-582
56. Nishikawa M., and Hashida M. Nonviral approaches satisfying various requirements for effective in vivo gene therapy. Biol. Pharm. Bull. 25 (2002) 275-283
57. Wooddell C.I., Van Hout C.V., Reppen T., Lewis D.L., and Herweijer H. Long-term RNA interference from optimized siRNA expression constructs in adult mice. Biochem. Biophys. Res. Commun. 334 (2005) 117-127
58. Bartlett D.W., and Davis M.E. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res. 34 (2006) 322-333
59. Takahashi Y., Nishikawa M., Kobayashi N., and Takakura Y. Gene silencing in primary and metastatic tumors by small interfering RNA delivery in mice: quantitative analysis using melanoma cells expressing firefly and sea pansy luciferases. J. Control Release 105 (2005) 332-343
60. Spänkuch B., Matthess Y., Knecht R., Zimmer B., Kaufmann M., and Strebhardt K. Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J. Natl. Cancer Inst. 96 (2004) 862-872
61. Stein U., Walther W., Stege A., Kaszubiak A., Fichtner I., and Lage H. Complete in vivo reversal of the multidrug resistance phenotype by jet-injection of anti-MDR1 short hairpin RNA-encoding plasmid DNA. Mol. Ther. 16 (2008) 178-186
62. Park S.Y., Lee W., Lee J., and Kim I.S. Combination gene therapy using multidrug resistance (MDR1) gene shRNA and herpes simplex virus-thymidine kinase. Cancer Lett. 261 (2008) 205-214
63. Zhang L., Gao L., Li Y., Lin G., Shao Y., Ji K., Yu H., Hu J., Kalvakolanu D.V., Kopecko D.J., Zhao X., and Xu D.Q. Effects of plasmid-based Stat3-specific short hairpin RNA and GRIM-19 on PC-3M tumor cell growth. Clin. Cancer Res. 14 (2008) 559-568
64. Zhang Y., Boado R.J., and Pardridge W.M. In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats. J. Gene Med. 5 (2003) 1039-1045
65. Maliyekkel A., Davis B.M., and Roninson I.B. Cell cycle arrest drastically extends the duration of gene silencing after transient expression of short hairpin RNA. Cell Cycle 5 (2006) 2390-2395
66. Bartlett D.W., and Davis M.E. Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Biotechnol. Bioeng. 97 (2007) 909-921
67. Eefting D., Grimbergen J.M., De Vries M.R., Van Weel V., Kaijzel E.L., Que I., Moon R.T., Löwik C.W., Van Bockel J.H., and Quax P.H.A. Prolonged in vivo gene silencing by electroporation-mediated plasmid delivery of small interfering RNA. Hum. Gene Ther. 18 (2007) 861-869
68. Robbins M., Judge A., Ambegia E., Choi C., Yaworski E., Palmer L., Mcclintock K., and Maclachlan I. Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum. Gene Ther. 19 (2008) 991-999
69. Kleinman M.E., Yamada K., Takeda A., Chandrasekaran V., Nozaki M., Baffi J.Z., Albuquerque R.J.C., Yamasaki S., Itaya M., Pan Y., Appukuttan B., Gibbs D., Yang Z., Kariko K., Ambati B.K., Wilgus T.A., Dipietro L.A., Sakurai E., Zhang K., Smith J.R., Taylor E.W., and Ambati J. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452 (2008) 591-597
70. Armstrong M.E., Gantier M., Li L., Chung W.Y., Mccann A., Baugh J.A., and Donnelly S.C. Small interfering RNAs induce macrophage migration inhibitory factor production and proliferation in breast cancer cells via a double-stranded RNA-dependent protein kinase-dependent mechanism. J. Immunol. (Baltimore, Md.: 1950). 180 (2008) 7125-7133
71. Mcbride J.L., Boudreau R.L., Harper S.Q., Staber P.D., Monteys A.M., Martins I., Gilmore B.L., Burstein H., Peluso R.W., Polisky B., Carter B.J., and Davidson B.L. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 5868-5873
72. Takahashi Y., Nishikawa M., Suehara T., Takiguchi N., and Takakura Y. Gene silencing of β-catenin in melanoma cells retards their growth but promotes the formation of pulmonary metastasis in mice. Int. J. Cancer 123 (2008) 2315-2320
73. Aagaard L., and Rossi J.J. RNAi therapeutics: principles, prospects and challenges. Adv. Drug. Deliv. Rev. 59 (2007) 75-86
74. Judge A., and Maclachlan I. Overcoming the innate immune response to small interfering RNA. Hum. Gene Ther. 19 (2008) 111-124
75. Spies B., Hochrein H., Vabulas M., Huster K., Busch D.H., Schmitz F., Heit A., and Wagner H. Vaccination with plasmid DNA activates dendritic cells via toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. J. Immunol. 171 (2003) 5908-5912
76. Yasuda K., Kawano H., Yamane I., Ogawa Y., Yoshinaga T., Nishikawa M., and Takakura Y. Restricted cytokine production from mouse peritoneal macrophages in culture in spite of extensive uptake of plasmid DNA. Immunology 111 (2004) 282-290
77. Cornélie S., Hoebeke J., Schacht A.M., Bertin B., Vicogne J., Capron M., and Riveau G. Direct evidence that toll-like receptor 9 (TLR9) functionally binds plasmid DNA by specific cytosine-phosphate-guanine motif recognition. J. Biol. Chem. 279 (2004) 15124-15129
78. Yoshida H., Nishikawa M., Yasuda S., Mizuno Y., and Takakura Y. Cellular activation by plasmid DNA in various macrophages in primary culture. J. Pharm. Sci. 97 (2008) 4575-4585
79. Mikuma T., Kawasaki H., Yamamoto Y., and Taira K. Overexpression of Dicer enhances RNAi-mediated gene silencing by short-hairpin RNAs (shRNAs) in human cells. Nucleic Acids Symp. Ser. (2004) 191-192
80. Yi R., Doehle B.P., Qin Y., Macara I.G., and Cullen B.R. Overexpression of Exportin 5 enhances RNA interference mediated by short hairpin RNAs and microRNAs. RNA 11 (2005) 220-226
81. Boudreau R.L., Monteys A.M., and Davidson B.L. Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. RNA 14 (2008) 1834-1844
82. Verma U.N., Surabhi R.M., Schmaltieg A., Becerra C., and Gaynor R.B. Small interfering RNAs directed against β-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin. Cancer Res. 9 (2003) 1291-1300
83. Huang W.S., Wang J.P., Wang T., Fang J.Y., Lan P., and Ma J.P. ShRNA-mediated gene silencing of β-catenin inhibits growth of human colon cancer cells. World J. Gastroenterol. 13 (2007) 6581-6587
84. Pu P., Zhang Z., Kang C., Jiang R., Jia Z., Wang G., and Jiang H. Downregulation of Wnt2 and β-catenin by siRNA suppresses malignant glioma cell growth. Cancer Gene Ther. (2008)